Nasal polyposis is a chronic inflammatory condition characterized by benign growths in the nasal passages and sinuses, affecting approximately 2.7% of adults. The incidence increases with age, peaking in individuals aged 50 years or older, while rare in children and adolescents. There is a high unmet clinical need for advanced therapies, as current treatment options, such as corticosteroids and surgery, offer limited efficacy and frequent recurrences. The growing focus on biologics and innovative nasal polyposis therapeutics is expected to drive pipeline development, addressing the need for long-term solutions and improving the quality of life for patients in the coming years.
The Nasal Polyposis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into nasal polyposis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for nasal polyposis. The nasal polyposis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The nasal polyposis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with nasal polyposis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to nasal polyposis.
Nasal polyposis is a chronic inflammatory disease characterized by benign, soft tissue growths in the nasal passages and sinuses. It occurs due to prolonged inflammation, often associated with conditions like asthma, allergies, or chronic rhinosinusitis. The disease impacts breathing, sense of smell, and quality of life. With rising prevalence in adults, especially those aged 50 and above, there is an urgent need for innovative therapeutic products, driving the development of targeted biologics and advanced drug candidates.
Nasal polyposis treatments currently include intranasal corticosteroids to reduce inflammation, surgery for severe cases, and antihistamines for allergy-related symptoms. However, these options often provide only temporary relief, with a high recurrence rate. Emerging therapies, such as biologics targeting inflammatory pathways, offer hope for long-term management by addressing the underlying causes of the disease. These advancements in nasal polyposis therapeutics aim to improve patient outcomes and reduce the burden of repeated interventions.
Nasal polyposis affects approximately 2.7% of adults, with incidence increasing with age, peaking in individuals aged 50 years and older. The condition is uncommon in children and adolescents. Nasal polyps are estimated to occur in 1% to 4% of the general population in the United States. The significant unmet clinical need for effective treatments drives the development of advanced nasal polyposis therapeutics, particularly biologic therapies.
This section of the report covers the analysis of nasal polyposis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II and IV covers a major share of the total nasal polyposis clinical trials.
The drug molecule categories covered under the nasal polyposis pipeline analysis include small molecules, monoclonal antibodies, immunomodulators, peptides, and RNA-based therapies. The nasal polyposis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for nasal polyposis.
The EMR report for the nasal polyposis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed nasal polyposis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in nasal polyposis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for nasal polyposis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of nasal polyposis drug candidates.
The Phase 3 study, sponsored by Optinose US Inc., aims to evaluate the efficacy and safety of OPN-375 186 μg twice daily in adolescents with bilateral nasal polyposis. This 16-week, double-blind, placebo-controlled study involves approximately 120 participants, aged 12-17 years. Completion is expected by March 2026, addressing nasal congestion and polyp reduction through innovative intranasal therapy.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is sponsoring a Phase II clinical trial to evaluate the efficacy, safety, and pharmacokinetics of TQC2731 injection in treating chronic rhinosinusitis with nasal polyps. This randomized, double-blind, placebo-controlled study involves around 80 participants. The study began in December 2023, with an estimated completion date of September 2025.
The Phase 1 study, sponsored by Trellis Bioscience LLC, aims to assess the safety, pharmacokinetics, and pharmacodynamics of TRL1068 in chronic rhinosinusitis with nasal polyps. TRL1068, a monoclonal antibody, eliminates biofilm to improve antibiotic effectiveness. With around 12 participants, the study commenced in January 2024 and is anticipated to be completed by January 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Nasal Polyposis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for nasal polyposis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into nasal polyposis collaborations, regulatory environments, and potential growth opportunities.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share